Matthew A. Hummel, Ph.D.

2004 University of Minnesota, Twin Cities, Minneapolis, MN 
Pharmacology, Pharmacy
"Matthew Hummel"
Mean distance: (not calculated yet)


Sign in to add mentor
Timothy S. Tracy grad student 2004 UMN
 (Assessment of multiple substrate binding in CYP2C9.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Mosher CM, Hummel MA, Tracy TS, et al. (2008) Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9. Biochemistry. 47: 11725-34
Hummel MA, Gannett PM, Aguilar J, et al. (2008) Substrate proton to heme distances in CYP2C9 allelic variants and alterations by the heterotropic activator, dapsone. Archives of Biochemistry and Biophysics. 475: 175-83
Hummel MA, Tracy TS, Hutzler JM, et al. (2006) Influence of fluorescent probe size and cytochrome b5 on drug-drug interactions in CYP2C9 Journal of Biomolecular Screening. 11: 303-309
Hummel MA, Locuson CW, Gannett PM, et al. (2005) CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant. Molecular Pharmacology. 68: 644-51
Tracy TS, Hummel MA. (2004) Modeling kinetic data from in vitro drug metabolism enzyme experiments. Drug Metabolism Reviews. 36: 231-42
Hummel MA, Gannett PM, Aguilar JS, et al. (2004) Effector-mediated alteration of substrate orientation in cytochrome P450 2C9. Biochemistry. 43: 7207-14
Hummel MA, Dickmann LJ, Rettie AE, et al. (2004) Differential activation of CYP2C9 variants by dapsone. Biochemical Pharmacology. 67: 1831-41
Hutzler JM, Kolwankar D, Hummel MA, et al. (2002) Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 1194-200
Tracy TS, Hutzler JM, Haining RL, et al. (2002) Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 385-90
See more...